The hormone prolactin (PRL) contributes to the pathogenesis of breast cancer in part through its activation of Jak2/Stat5, a PRLr-associated pathway dependent upon crosstalk signaling from integrins. It remains unclear, however, how this cross-talk is mediated. Following PRL stimulation, we show that a complex between the transmembrane glycoprotein signal regulatory protein-α (SIRPα) and the PRLr, β1 integrin, and Jak2 in ER+ and ER-breast cancer cells is formed. Overexpression of SIRPα in the absence of collagen 1 significantly decreased PRL-induced gene expression, phosphorylation of PRLr-associated signaling proteins, and PRLstimulated proliferation and soft-agar colony formation. In contrast, overexpression of SIRPα, in the presence of collagen 1 increased PRL-induced gene expression, phosphorylation of Jak2, Stat5 and Erk, and PRL-stimulated cell growth. Interestingly, overexpression of a tyrosinedeficient SIRPα (SIRPα-4YF) prevented the signaling and phenotypic effects mediated by WT-SIRPα. Furthermore, overexpression of a phosphatase-defective mutant of Shp-2 or pharmacologic inhibition of Shp-2 produced effects comparable to that of SIRPα-4YF.
was diluted to 15ug/ml in 50mM Tris pH 8.0 and added to the collagen 1 coated dishes overnight at 4°C. The next day heat-denatured 3% BSA-PBS was added to the tissue culture dishes for 30 minutes at 37°C. This was aspirated off and cells were then seeded accordingly.
Luciferase assay: T47D transfectant pools were plated in the absence or presence of collagen 1, grown in complete media and transiently transfected with 1μg of either pGL4-CISH reporter as well as DN-Shp-2 (courtesy of Dr. E. Fuch) and 10ng of pGL4-Renilla according to LF2000 manufacturers protocol (Invitrogen). Twenty-four hours after transfection the cells were arrested in defined PRL deficient media for an additional twenty-four hours. The cells were stimulated with 250ng/ml of PRL (courtesy of Dr. T. Kossiakoff) for twenty-four hours and analyzed for dual luciferase on a Victor3V (Perkin-Elmer). Cells treated with sodium stibogluconate (courtesy of Dr. E. Eklund, SSG 100ng/ml) were pre-treated for four hours prior to PRL stimulation. Results were reported as luciferase/renilla ratio (±) SEM.
Immunoprecipitation and immunoblotting: T47D, T47D transfectant pools and MDA-MB-231 cells were grown in complete media and arrested in defined PRL deficient media for twentyfour hours. They were treated with 250ng/ml of PRL for times indicated. The cells were harvested, lysed in RIPA buffer [35] and immunoprecipitated with either SIRPα (Chemicon 1μg/sample), Jak2 (Cell Signaling, 1μg/sample), β1 integrin (Chemicon, 1ug/sample) or PRLr by SDS-PAGE and transferred to PVDF filters. The filters were blocked in 0.6% blotto for one hour. Following blocking the blots were incubated with the appropriate primary antibody overnight at 4°C and then HRP-conjugated secondary antibody for one hour at room temperature. Chemiluminescence was detected with ECL plus (Amersham) and images were collected on a CCD camera (Fuji). All blots were quantitated via scanning densitometry (Fuji, Image gauge software) and numbers reported represent fold decrease or increase as compared to the control transfectants.
Proliferation assay: T47D and MDA-MB-231 transfectants were plated in the absence and presence of collagen 1. Twenty-four hours after plating the transfectants were arrested in defined PRL deficient media for twenty-four hours. The cells were then treated with or without 250ng/well of PRL for seventy-two hours and 3 H thymidine (0.5μCi/well) was added for four hours. The cells were lysed on a Filtermat Harvester (Perkin-Elmer) and transferred to a Filtermat (Wallac) and read on a Microbeta Luminescence counter (Perkin-Elmer).
Soft agar colony formation: T47D transfectant pools were suspended in 0.3% agar/regular growth media/PRL mix in the presence or absence 10% collagen 1. Once solidified an overlay of regular growth media/PRL (250ng/ml) was added and changed every two days. Cells were photographed twenty-four hours after suspension and then starting on day seven on Magnafire software (Optronics). Colony size and numbers were counted with ImageJ software (NIH) and results were analyzed by comparing number and size of colonies of control transfectant pools to the WT-SIRPα transfectants.
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Statistical Analysis: All experiments described were performed no less than three times.
Statistical analysis was performed on Graph-Pad Prism 4 (Graph-Pad Software) and results are shown as the means with error bars depicting (±) SEM. One-way ANOVA statistical tests were performed and p-values were reported.
Results:
SIRPα interacts with the PRLr, β1 integrin and Jak2 in breast cancer cells
Given literature that indicated that SIRPα could influence GHr signaling [21, 34] , we sought to examine if SIRPα could interact and influence PRLr action in the context of breast cancer. To that end, the interaction of SIRPα with the PRLr, β1 integrin and Jak2 was tested in MDA-MB-231 was comparable to that seen in the T47D cells ( Figure 1B ). However, in these cells, unlike T47D, the data suggested that β1 integrin and the PRLr appear to be associated with each other in the absence of PRL and this interaction was enhanced upon PRL stimulation.
To better examine the interactions of SIRPα with β1 integrin and Jak2, three stable T47D transfectant pools (Figure 2A , B and E) were created. These three stable transfectant pools were generated to overexpress wild type SIRPα (WT-SIRPα), GFP (control), or a non-phosphorylated mutant SIRPα (SIRPα-4YF), which is in-active in these cells therefore mimicking the control transfectants with endogenous SIRPα. Overexpression was assessed in WT-SIRPα and SIRPα-4YF transfectant pools by immunoblot analysis. Investigation in these transfectants revealed two fold higher SIRPα protein expression than that of the control ( Figure 2E ). Coimmunoprecipitation analysis of these transfectants ( Figure 2C ) revealed that SIRPα interacted with β1 integrin in the control transfectants as well as the SIRPα overexpression transfectants within one minute of PRL stimulation and this interaction was maintained through sixty minutes ( Figure 2A) . Interestingly, the mutant form of SIRPα also interacted at early time points with β1 integrin which suggested that the four tyrosine residues in the SIRPα intra-cellular domain are not required for this interaction. Additionally, co-immunoprecipitation analysis also revealed that SIRPα interacted with Jak2, independent of ligand addition in the SIRPα overexpression transfectants ( Figure 2B ). Of importance, each co-immunpreciptation was performed three separate times and reported as fold induction as compared to the untreated control sample ( Figure 1A , 1B, 2C and 2D). Taken together these associations confirmed that SIRPα, the PRLr, 
PRL-induced CISH promoter luciferase activity and protein expression is enhanced by
SIRPα in a collagen 1/β1 integrin-dependent manner.
Given the requirement for integrins during PRLr signaling [14] , PRL-responsive CISH reporter luciferase activity was utilized to examine the effects of SIRPα overexpression on PRLmediated gene expression both in the presence and absence of several different ECM substrates (Table 1) . Results verified that overexpression of SIRPα inhibited PRL-induced CISH promoter luciferase activity in transfectants when plated on the ECM proteins laminin and fibronectin.
These ECM proteins are typically found in the basement membrane niche of the normal ductallobular unit. In contrast, SIRPα overexpression transfectant pools plated on collagen 1 (a structural protein of the interstitial space) showed an enhancement of PRL-induced CISH promoter luciferase activity as compared to the control or SIRPα-4YF transfectant pools (Table   1 and Figure 3B ). Comparable results were obtained with two independent preparations of collagen 1 (data not shown). These data suggested that SIRPα may differentially regulate PRLinduced CISH luciferase activity depending on ECM occupancy.
In light of data in Table 1 , PRL-induced CISH ( Figure 3A and 3B) promoter luciferase activity was examined in transfectant pools overexpressing SIRPα plated in the presence or absence of collagen 1. These analyses revealed that the transfectant pools overexpressing SIRPα plated in the absence of collagen 1 showed a significant decrease in PRL-induced CISH promoter luciferase activity. This effect was lost in transfectants which overexpressed the control and SIRPα-4YF constructs ( Figure 3A ). In contrast, the transfectants overexpressing Figure 3D ). Thus, these data revealed that SIRPα overexpression differentially regulated PRL-induced CISH promoter luciferase activity and endogenous PRL-dependent CISH protein expression.
To further assess the involvement of β1 integrin on PRL-induced CISH promoter luciferase activity in the presence of collagen 1, a neutralizing anti-β1 integrin antibody was utilized. Data in Figure 4 revealed that transfectants overexpressing SIRPα plated in the presence of collagen 1 and anti-β1 integrin showed a reduction in PRL-induced CISH promoter luciferase activity as compared to the transfectants overexpressing SIRPα plated in the presence of collagen 1 only. Interestingly, the reduction resembled results observed in the cells overexpressing SIRPα plated in the absence of collagen 1. Consequently, the data revealed that SIRPα-mediated potentiation of PRL-induced CISH promoter luciferase activity is dependent on the activity of β1 integrin in the presence of collagen 1.
Differential regulation of PRLr signaling as a function of SIRPα overexpression
Since SIRPα overexpression modulated PRL-induced gene expression, it was reasoned that this might be due to its modulation of downstream molecules in the PRLr signaling network.
Results in Figure 5 This data further supports the notion that the differential regulation of PRLr signaling by SIRPα extends to the cellular level in breast cancer.
To further assess the effect of SIRPα overexpression on the biology of T47D breast cancer cells the transfectants overexpressing SIRPα were examined in soft agar. In Figure 7A , the cells were plated in a 100% soft agar/media/PRL mixture and allowed to grow for 15 days.
In the absence of collagen 1 there was a significant reduction of size and number of colonies in the SIRPα overexpression transfectants as compared to the control transfectants ( Figure 7C ). In contrast, adding 10% collagen 1 ( Figure 7B ) completely reversed the outcome, as SIRPα overexpression resulted in a significant increase in colony number and size when compared to the control or SIRPα-4YF transfectants ( Figure 7C ). Thus, comparable to the above results, SIRPα can function as a signaling switch that can increase or decrease soft agar colony formation in a collagen 1-dependent manner.
DN-Shp-2 or Sodium Stibogluconate (SSG) reversed the effect of SIRPα overexpression on PRL-induced CISH promoter luciferase activity in the absence or presence of collagen 1
The above results suggested that SIRPα regulation of PRL-mediated signaling could induce the activity of the Shp-2 phosphatase ( Figure 5 ). To test this hypothesis, two approaches were utilized to investigate the contribution of Shp-2 in the actions of SIRPα: overexpression of DN-Shp-2 or the use of a Shp-2 inhibitor SSG. As seen in Figure 8A , DN-Shp-2 co-expression As seen in Figure 8C , SSG treatment of SIRPα overexpression transfectants reversed its effect on PRL-induced CISH promoter luciferase activity in the absence of collagen 1. In contrast, the SIRPα overexpression transfectants plated on collagen 1 showed diminished luciferase activity equivalent to the control or SIRPα-4YF transfectants in the presence of SSG ( Figure 8D ).
Again, these data parallel the results obtained with DN-Shp-2, further confirming that SIRPα is a Shp-2-dependent signaling switch in the PRL/PRLr pathway in breast cancer cells.
Discussion:
SIRPα activation and modulation has been well documented in neurons, macrophages and myeloid cells, however, this is the first report describing its function in breast cancer cells [37, 38] . SIRPα has one known ligand, CD47, but can also be activated by various ligand engaged cell surface receptors including integrins [18, 37] . CD47, also named integrin- These novel data suggest that collagen 1 (a β1 integrin ligand) promotes a functional switch in SIRPα's regulation of the PRLr pathway from that of a negative regulator to that of a positive regulator. Taken together, our data in Figures 1-4 and Table 1 SIRPα is phosphorylated on its four cytoplasmic tyrosine residues in response to growth factors, hormones and integrins [46] . The phosphorylation of SIRPα leads to the recruitment, binding, phosphorylation and activation of Shp-2 as well as Shp-1 [21, 34] . There is some debate in the literature as to whether the phosphorylation of Shp-2 confers activity. However, recent studies suggest that the phosphorylation of Shp-2 leaves it in an open conformation allowing it to act as a phosphatase [47, 48] . Several studies have demonstrated that Shp-2 positively effects the MapK as well as the Jak2/Stat5 signaling cascade [13, 25, 49] . Conversely, Shp-2 has also been shown to negatively regulate Stat family proteins including Stat 1,-3, and -5 in different cell types by the de-phosphorylation of up-stream Jak family kinases. In the mammary gland, Shp-2 regulates PRLr signaling by inhibiting the activity of both Jak2 and Stat5 [21, 26] . Our data revealed that in the presence of collagen 1 SIRPα overexpression decreased Shp-2 phosphorylation. However, in the absence of collagen 1 there was an increase in Shp-2 phosphorylation ( Figure 5 ). This dual regulation may be a direct result of SIRPα's ability to alter Shp-2 activation in the presence or absence of collagen 1-bound integrins. Given that: 1) Use of the Shp-2 inhibitor SSG resulted in comparable effects to DN-Shp-2. SSG is currently used in the treatment of Leishmania however, its mechanism of action has been incompletely understood [50] . A recent study demonstrated SSG as an effective inhibitor of Shp-2. In addition, this study implied that SSG may be effective in the treatment of AML by overcoming cancer cell resistance to IFN treatment [36] . In support of this notion, it was demonstrated that using SSG as a single agent in a dose-dependent manner inhibited the growth of prostate, breast, bladder and colon cancer cells in culture [36] . Our data shows that SSG blocks the effects of SIRPα overexpression on ECM-modulated, PRL-driven gene expression ( Figure 8C and D) . Collectively, our data suggests that SIRPα's mechanism of action are through the phosphatase Shp-2, and that a PTP inhibitor such as SSG could be used alone or in combination with other anticancer therapies effectively in the treatment of ER+ and ER-breast cancers.
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